Business Wire

“‘Someday’ is Now!”: Anpac Bio & Med Partners Celebrate ‘National Cancer Prevention Month’ Surpassing 60,000 ‘Liquid Biopsy’ Cases

Jaa

Anpac Bio-Medical Science Company (Anpac Bio), and its internationally-acclaimed medical research partners and hospitals, are celebrating “World Cancer Day” (#WorldCancerDay) and “National Cancer Prevention Month” (#NationalCancerPreventionMonth) by surpassing a new, global milestone: processing over 60,000, independently-corroborated cases of Anpac Bio’s proprietary, “Cancer Differentiation Analysis” (CDA) liquid biopsy tests worldwide.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180204005101/en/

Anpac Bio-Medical Science Company CEO Dr. Chris Yu inspects one of the company's proprietary "Cancer ...

Anpac Bio-Medical Science Company CEO Dr. Chris Yu inspects one of the company's proprietary "Cancer Differentiation Analysis" (CDA) liquid biopsy technology devices before screening simple, standard blood tests signals of early disease. Anpac Bio's CDA technology consistently detects 26+ cancers, with a 75%-90% sensitivity/specificity rates, usually identifying the disease at its earliest stages. And it does so without any harmful side effects in patients; generating far fewer "false positives"; at a cost substantially lower than traditional testing; and generating results within minutes of sample submission. Fully-commercialized with 200 patents filed worldwide, Anpac Bio and its respected medical research partners are celebrating #NationalCancerPreventionMonth by surpassing a new global milestone: processing 60,000+ independently-corroborated CDA tests for early cancer screening and detection; as well as monitoring cancer treatment, effectiveness, and recurrence. (Photo: Business Wire)

World-renowned, Second Military Medical University and its affiliated Changhai Hospital (CH) in Shanghai, China, have conducted 4,000+ CDA liquid biopsy tests since 2014. Submitting Lung, Esophageal Cancer, and cancer-free control group blood samples, “blinded” to Anpac Bio, CH concluded CDA is a remarkably accurate, non-invasive test, supporting both early diagnosis, and monitoring treatment effectiveness, prognosis, and recurrence.

“Our preliminarily results indicate that CDA technology has better sensitivity and specificity for early diagnosis, as well as potentially a good tool for treatment assessment for Lung Cancer and Esophageal Cancer than traditional tumor markers,” reports Dr. Jun-Jie Wu, Deputy Chief Physician, CH Department of Oncology. “It (CDA) can also play a good role in complementing chest CT (Computerized Axial Tomography) screening for pulmonary nodules. The existing data suggests that CDA technology is a promising technology in the field of diagnosis and treatment assessment of Lung Cancer and cancer of the Esophagus.”

Described as “game changing” and receiving the “Breakthrough Innovation Award” at the World Nobel Prize Laureate Summit; and named “Most Promising Cancer Screening Company” at the 2017 Global Precision Medicine Industry Awards , Anpac Bio’s CDA technology effectively reinvents early cancer screening and detection.

By analyzing simple, standard, blood tests, and applying Anpac Bio’s proprietary, multi-level, multi-parameter, diagnostic algorithms, Anpac Bio’s CDA technology identifies cancer with measurably-greater accuracy than most current, conventional screening methods. And it does so without any harmful side effects in patients; generating far fewer “false positives”; at a cost substantially lower than traditional testing; and generating results within minutes of sample submission.

Comprehensive research validity data from 60,000+ cases processed to date demonstrate CDA diagnostics consistently detects 26+ cancers -- with a sensitivity and specificity rate range of 75%-90% -- usually identifying the disease at its earliest stages.

The Oncology Department of Shanghai Changzheng Hospital (SCH) corroborates these results. Since 2016, SCH has conducted two comprehensive clinical research studies of Anpac Bio’s CDA liquid biopsy technology. Submitting over 500 healthy “control” group; “high-risk” group (those genetically or environmentally pre-disposed to developing cancer); and independently-diagnosed and “confirmed cancer” group blood samples; for CDA analysis.

According to study director and SCH Deputy Professor Dr. Yuan Sheng Zang: “Initial results indicated that CDA technology has better sensitivity and specificity for early-stage cancer screening than that of traditional tumor markers. The evaluation on the significance of CDA technology in prognosis is ongoing. The existing research data suggest that CDA technology has a good prospect in the field of cancer diagnosis and prognosis.”

Pioneering liquid biopsy research (launched in 2008), Anpac Bio is already, fully-commercialized and generating revenue from Fortune 500 corporate, insurance, medical, research, and individual (“over the counter”) testing; while most competing “liquid biopsy” research remains in the laboratory and unavailable to the general public (for perhaps years).

Additionally, competing tests generally measure only single/few sample indicators (such as gene mutations that may indicate a patient’s increased risk or probability of potentially developing cancer at some point). Anpac Bio’s CDA is a “functional biology” test – providing medical professionals important information regarding actual disease signals present in the patient’s body at the moment of blood draw.

CDA’s independently-confirmed, very early stage cancer and pre-cancerous disease detection’s efficiency and accuracy is due to the technology’s multi-level and multi-parameter, patented design. With over 200 CDA-related patent applications worldwide (65+ currently issued), CDA’s integrated system measures numerous protein, molecular, cellular, and other factors, to identify disease signals. By enhancing signal detection and processing, while reducing “noise”, the collected data is subsequently analyzed using Anpac Bio’s proprietary algorithms.

The resulting data is then assigned an overall value, called “CDA Value”, indicating cancer incidence risk level (the higher the CDA Value, the higher the cancer risk). CDA’s accuracy and advantages have been verified in previous studies, and presented before respected scientific organizations, such as the American Society of Clinical Oncology (ASCO), the Breast Cancer Symposium, and the World Nobel Prize Laureate Summit.

“Every day, our company hears of other, potential ‘liquid biopsy’ tests that report ‘someday’ may be used to catch cancer,” states Dr. Chris Yu, Anpac Bio Chief Executive Officer. “Our CDA technology has been extensively tested, verified, and used daily by dozens of Asia’s most well-respected and renowned medical institutions. We are also generating equally accurate and positive results in the United States. We’re very proud that our CDA devices have advanced well-beyond the laboratory and are processing real tests for real people – saving lives every day. On this ‘National Cancer Prevention Month’, Anpac Bio and our medical partners want the world to know: ‘Someday’ is now!”

For more information about Anpac Bio please check: www.AnpacBio.com.

Contact information

Anpac Bio-Medical Science Company
Drisha Leggitt, 916-206-2553
Drisha_Leggitt@AnpacBio.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Tracxpoint Signed a Major Agreement to Deploy its Artificial Intelligence Cart (AiC®) Platform at CONAD, One of the Largest and Most Sophisticated Supermarket Chains in Italy with 3,000 Locations in Lieu of Amazon Go after Intensive Study10.12.2018 14:00Tiedote

Tracxpoint, a global provider of next-generation self-checkout grocery solutions, today announced an agreement to roll out its Artificial Intelligence Cart (AiC®) at CONAD DEL TIRRENO, one of the seven cooperatives of CONAD’s chain with more than 3,000 supermarket stores in Italy. This is a major milestone for the Israeli startup in its mission to establish the AiC® platform as the most powerful, accessible and comprehensive solution for self-checkout and personalized in-store engagement on the market today. CONAD DEL TIRRENO will start implementing the AiC® ecosystem during 2019. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181210005176/en/ The Tracxpoint AiC enables checkout-free stores and personalized in-store engagement for Italy's largest supermarket chain, CONAD. (Photo: Business Wire) In direct contrast to capital-intensive and smaller store concepts like Amazon Go or its imitators that rely on ceiling cameras for

Jetex Now the Exclusive Dealer in the Middle East for Hi-Tech New HondaJet10.12.2018 12:52Tiedote

Jetex is bringing the next-generation in advanced private jets to the Middle East after striking an agreement with Honda Aircraft Company to become the exclusive authorized dealer for the region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181210005273/en/ Adel Mardini of Jetex signs with Simon Roads of Honda Aircraft Company (Photo: AETOSWire) The deal means Jetex is now the manufacturer’s sole representative for the new HondaJet offering sales and support across the Gulf and Middle East region. “With Honda’s brand strength and recognition in the Middle East, we have received tremendous interest in the HondaJet Elite. We are proud to appoint Jetex as HondaJet Middle East to provide our customers with a committed sales team in the region for the world’s most advanced very light jet,” said Honda Aircraft President and CEO Michimasa Fujino. “We are proud to be chosen by Honda Aircraft Company and excited to be awarded the r

China Shanghu Builds Itself into an International Health Demonstration Zone10.12.2018 12:16Tiedote

On October 25, 2018, the 13th Meeting of the Conference of the Contracting Parties to the Ramsar Convention on Wetlands declared that Changshu was put on the list of the first “International Wetland Cities” in the world, in recognition of its success in the protection of wetland ecology. The award is arguably the most influential on a global scale—supreme and unchallenged. It was against this backdrop that the project of Changshu Shanghu International Health Demonstration Zone was commenced. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181210005254/en/ 2025 Shanghu International Health Demonstration Zone (Photo: Business Wire) Covering an area of about 40 million square meters, Changshu Shanghu, a national wetland park, is slap bang in the middle of the city, including 800-hectare ecological lake, four parks and ten places of interest. In compliance with the strategy for Healthy China 2030, the characteristic “Modern Healt

KOKUYO's "360° Gliding Chair ing" Wins FRAME Awards ORGATEC 2018 in Two Categories10.12.2018 12:00Tiedote

KOKUYO Co., Ltd. (TOKYO:7984), a leading provider of office design and furniture in Japan, won FRAME Awards for "360º Gliding Chair ing" in two categories at ORGATEC 2018, “Trade Fair Stand of the Year” and “Best Use of Light,” which is organized by the Dutch interior design magazine "FRAME." This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181210005248/en/ KOKUYO's "360° Gliding Chair ing" Wins FRAME Awards ORGATEC 2018 (Photo: Business Wire) ORGATEC 2018, the largest International Trade Fair for Furnishing and Management of Offices and Office Facilities was held from October 23 to 27 in Cologne, Germany. Internationally renowned creators and critics from Amsterdam, Berlin, and elsewhere in Europe were the judges of FRAME Awards critiquing global furniture manufacturer booths in four categories: Best Use of Colour, Best Use of Light, Best Use of Material, and Trade Fair Stand of the Year. Winners in these categories will be h

SIAE MICROELETTRONICA Outperforms Telefónica 10Gbps E-band Tests to Power 5G Backhauling10.12.2018 11:00Tiedote

Telefónica a global leader mobile operator and SIAE MICROELETTRONICA a leader in wireless transport technology have put to the test the high capacity 10Gbps wireless links to enhance the backhauling network for the future advent of 5G. The millimetre-wave point-to-point radio operating at 80GHz E band carrier, offers the lowest transport latency and the highest wireless capacity of 10Gbps over a single channel, satisfying the strict 5G requirements. Telefónica successfully field tested SIAE MICROELETTRONICA millimetre-wave radio solution in two use cases: 10Gbps point-to-point links addressing urban applications and the multicarrier link aggregation addressing the sub-urban applications, pushing high capacity connectivity to longer distances. “SIAE MICROELETTRONICA and Telefónica have cooperated over multiple projects all aiming to satisfy the 5G backhaul requirements. From microwave SDN applications to the introduction of state of the art millimetre-wave radio, once again crossing tog

Fishawack Acquires Creative Consultancy Blue Latitude Health10.12.2018 10:00Tiedote

The Fishawack Group of Companies, one of the world’s largest independent medical communications and medical marketing organizations, has acquired Blue Latitude Health, based in London, UK, and New York, USA. Blue Latitude Health is a creative consultancy combining the commercial focus of a consultancy with the creative vision of an agency. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181209005023/en/ Dominic Miller, Fred Bassett, Oliver Dennis (back row from left to right), Martin Brass, Gail Flockhart (front row from left to right). (Photo: Business Wire) “In 2016, we set out our vision to form a major new force in the global creative agency space that would make us as strong in the creative arena as we already are in medical communications,” explained Oliver Dennis , Chief Executive Officer of the Fishawack Group. “With three acquisitions in this space in the last 16 months, I think we’ve firmly announced our intention t

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme